Classes
DEA Class; Rx
Common Brand Names; Varubi
- Antiemetic Agents;
- NK1 Receptor Antagonists
Description
Substance P/neurokinin 1 (NK1) receptor antagonist
Used in combination with dexamethasone and a 5-HT3 receptor antagonist for the prevention of CINV
Contraindicated with CYP2D6 substrates with a narrow therapeutic index, such as thioridazine and pimozide
Indications
Indicated for delayed chemotherapy-induced nausea/vomiting prophylaxis, in combination with other antiemetic agents.
Contraindications
Coadministration with CYP2D6 substrates with a narrow therapeutic index (eg, thioridazine and pimozide)
Hypersensitivity to any component of the product
<2 years of age
Adverse Effects
Tablets
HEC
Neutropenia (9%)
Hiccups (5%)
Abdominal pain (3%)
MEC
Decreased appetite (9%)
Neutropenia (7%)
Dizziness (6%)
Dyspepsia (4%)
Urinary tract infection (4%)
Stomatitis (4%)
Anemia (3%)
Pregnancy and Lactation
Limited data in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcome
Unknown if distributed in human breast milk and no data on effects on breastfed infant or on milk production
Maximum Dosage
180 mg orally or 166.5 mg intravenously as a single dose on day 1 of the chemotherapy regimen.
180 mg orally or 166.5 mg intravenously as a single dose on day 1 of the chemotherapy regimen.
Safety and efficacy have not been established.
Safety and efficacy have not been established.
How supplied
Rolapitant
tablet
- 90mg
